Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by HilleVax, Inc. HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress August 08, 2024 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax Announces Reduction in Force July 31, 2024 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants July 08, 2024 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress May 09, 2024 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress March 20, 2024 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference February 05, 2024 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer January 18, 2024 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China January 08, 2024 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress November 09, 2023 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax to Present at Upcoming Investor Conferences November 01, 2023 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference September 26, 2023 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares September 25, 2023 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax Announces Pricing of Public Offering of Common Stock September 19, 2023 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax Announces Proposed Public Offering of Common Stock September 19, 2023 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress August 14, 2023 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress May 12, 2023 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors May 09, 2023 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate April 25, 2023 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress March 17, 2023 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax Announces Executive Management Appointments and Promotions January 09, 2023 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference January 04, 2023 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate December 05, 2022 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax to Participate in November Investor Conferences November 10, 2022 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress November 10, 2022 From HilleVax, Inc. Via GlobeNewswire Tickers HLVX HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate September 08, 2021 From HilleVax, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
